Randomized, Double-Blind, Placebo-Controlled Trial Of Evofosfamide (Evo) And Pemetrexed (Perm) In Advanced Non-Squamous Non-Small Cell Lung Cancer (N-S Nsclc).

Tibor Csoszi,Jonathan W. Goldman,Mária Szilasi,Joachim von Pawel,Silvia Novello,Corey A. Carter,Tudor-Eliade Ciuleanu,Alessandro Del Conte,Gurkamal S. Chatta,Michael Schenker,Francisco Robert,Sergey Orlov,Katarzyna Zajda,Filippo De Marinis,Charles L. Bennett,Stew Kroll,Tillman E. Pearce,Chandra P. Belani

JOURNAL OF CLINICAL ONCOLOGY（2016）

引用 0|浏览21

暂无评分

摘要

9075Background: Tumor hypoxia is associated with chemo- and radioresistance. Evo is a hypoxia-activated prodrug that releases the bis-alkylating DNA crosslinker Br-IPM when reduced in severe hypoxi...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要